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A 67-year-old man received left radical nephrectomy for left renal cell carcinoma (RCC) (clear cell
carcinoma, G2, pT3bN0M0). After 9 months, he presented with an acute onset of left extremity edema. A
computed tomographic (CT) scan and magnetic resonance imaging reveal recurrent renal cell carcinoma in
the inferior vena cava (IVC) and the left renal fossa, thrombus in the left external vein and acute pulmonary
embolism. We performed treatment with sunitinib for 5 months after anticoagulant therapy for 3 weeks.
A new CT scan showed disappearance of RCC in the IVC and reduction in the size of RCC in the renal
fossa. Only 11 cases are reported as recurrent RCC in the IVC. We report the first case of recurrent
intracaval RCC in which sunitinib treatment was effective.
(Hinyokika Kiyo 56 : 499-503, 2010)
























瞭で被膜を伴う径 9 cm 大の淡黄色腫瘍を認め，左腎
静脈内腫瘍塞栓は断端から離れていた．病理組織学的










(Fig. 2）．腹部造影 CT 検査で同様の所見を認め (Fig.
1b），その他に左外腸骨静脈血栓，微小肺血栓症を認
めたため，抗凝固療法目的で緊急入院した．




入院時検査所見 : 末梢血，血液生化学検査で Cr
1.27 mg/dl，CRP 2.30 mg/dl，D dimer 3.5 μg/dl と上







Fig. 1. a) MRI shows a 9 cm left renal tumor which extended into the left renal vein. b) CT scan shows recurrent
renal cell carcinoma in the IVC and the left renal fossa. c) CT scan shows disappearance of RCC in the IVC
and reduction in the size of RCC in the renal fossa after 5 courses of sunitinib treatment.
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Fig. 2. MRI shows recurrent renal cell carcinoma in the IVC, the left common iliac vein and the left renal vein.











た (Fig. 1c）．National Cancer Institute Common Toxicity
Criteria に基づく治療中の有害事象として grade 1 の








































Med2) で調べた限り IVC 浸潤を伴う腎細胞癌に対す
Table 1. Review of previous reports of post-operative recurrent RCC in the IVC












Stage II Unknown 右 10 IVC (level I) IVC thrombectomy
2 Barone 1991 57 Male 易疲労感 Unknown Unknown 左 120 IVC-RA (levelIV), renal fossa
IVC thrombectomy
and resection of
tumor in the renal
fossa
3 Uygur 2001 54 Male なし T1bN0M0 Clear,mod 右 48 IVC (level III) IVC thrombectomy





5 Ioannis 2003 53 Female 息切れ Unknown Unknown 右 60 IVC-RA(level IV) IVC thrombectomy
6 Minervini 2004 65 Male なし T3bN0M0 Clear, G2 右 20 IVC (level II) IVC thrombectomy
7 Horger 2004 55 Female なし T3bN0M0 Clear, G3 右 42 IVC (level III) Caval resection
8 Smaldone 2006 58 Female 下腿浮腫 T1N0M0 Clear 右 12 IVC (level III) IVC thrombectomy
9 77 Male 下腿浮腫 T3bN0M0 Clear 右 48 IVC (level III) Caval resection
10 51 Male 下腿浮腫 T3cN0M0 Clear 右 6 IVC (level III) Caval resection andgraft replacement
11 自験例 2009 67 Male 左下肢浮腫 T3bN0M0 Clear, G2 左 9
IVC (level II),
LN Sunitinib
IVC : inferior vena cava, LN : lymph node. Classification by tumor thrombus level, level 0 : thrombus limited to the renal vein, level I :
thrombus extending into IVC, ＜2 cm above the renal vein, level II : thrombus extending ＞2 cm above the renal vein but below the hepatic
veins, level III : thrombus at the level of or above the hepatic veins, but below the diaphragm.
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る手術療法に分子標的療法を併用した報告を 3例検索
することができた (Table 2)10,11)． 2例が neoadjuvant
therapy で使用しており，内訳は sunitinib 1例，
sorafenib 1例であった． 1 例が adjuvant therapy で
sunitinib を使用していた．わずか 3例ではあるが，原
発巣が「固形癌の治療効果判定のための新ガイドライ
ン (RECIST)｣ の評価で安定 (stable disease ; SD) で
あっても，IVC を含む転移巣では部分奏効 (partial
response ; PR) や完全奏効 (complete response ; CR) と
なっている．詳細を見ていくと neoadjuvant therapy を
























一方，No 2 は sunitinib 5 コース施行後に second look
surgery を施行している．再手術のため癒着が強くリ
ンパ節を完全に摘出することは出来ず，摘出検体で腫
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